ADRB2 and neuroblastoma: Although additional studies are required to determine whether β2-AR protein levels or other biomarkers predict which tumors are most sensitive to beta blockade in vivo our results suggest the majority of NB tumors express ADRB2 and thus may respond to β-AR antagonists.